RT combined with ICIs shows promising improvements in survival and tumor response compared to ICI alone in advanced HCC, albeit with increased toxicity. Large randomized trials are needed to confirm efficacy, optimize RT regimens, and identify patients most likely to benefit.
Saqib et al. (Thu,) studied this question.